Celldex Therapeutics, Inc.CLDXNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+43.9%
5Y CAGR+43.3%
Year-over-Year Change
Research and development spending
3Y CAGR
+43.9%/yr
vs +5.5%/yr prior
5Y CAGR
+43.3%/yr
Consistent
Acceleration
+38.4pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
6x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $245.10M | +49.9% |
| 2024 | $163.55M | +38.6% |
| 2023 | $118.01M | +43.5% |
| 2022 | $82.26M | +44.8% |
| 2021 | $56.81M | +40.2% |
| 2020 | $40.53M | -5.0% |
| 2019 | $42.67M | -35.8% |
| 2018 | $66.45M | -30.9% |
| 2017 | $96.17M | -6.4% |
| 2016 | $102.73M | - |